NEOGEN CORP

CEO Nassif Mikheal’s recent 505‑share buy at $11.95 shows quiet confidence in Neogen’s growth, hinting that insiders see value amid rising revenue and a tighter loss.

NEOGEN insider sale shows routine tax‑cover moves; executives stay bullish, backing a rising diagnostics platform with strong 110% gains.

Neogen Corp’s insider buying spree shows cautious yet confident growth, with Moylan’s May 4 trades hinting at future value plays amid earnings rebound.

Neogen CEO Nassif Mikheal’s latest 137‑share purchase signals confidence in a volatile, low‑priced stock, offering investors a low‑cost entry point and a cue to monitor future insider buying.